4540.T
TSUMURA & CO.
プライム · 医薬品 · 医薬品 · JP
JPY 3,751.00
−0.77%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 192.6B | 192.6B | 181.1B | 150.8B | 140.0B |
| Cost of Revenue | 22.6B | 101.1B | 90.5B | 82.0B | 71.8B |
| Gross Profit | 20.5B | 91.5B | 90.6B | 68.8B | 68.3B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 12.8B | 56.3B | 50.5B | 48.8B | 47.4B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 12.8B | 56.3B | 50.5B | 48.8B | 47.4B |
| Cost and Expenses | 157.4B | 157.4B | 141.0B | 130.8B | 119.1B |
| Operating Income (EBIT) | 35.2B | 35.2B | 40.1B | 20.0B | 20.9B |
| Non-Operating | |||||
| Interest Income | 94.0M | 573.0M | 628.0M | 671.0M | 531.0M |
| Interest Expense | 147.0M | 1.1B | 518.0M | 330.0M | 256.0M |
| Net Interest Income | (53.0M) | (479.0M) | 110.0M | 341.0M | 275.0M |
| Other Non-Op Income/Expense | (1.5B) | 4.8B | 2.3B | 3.5B | 2.5B |
| Non-Operating Income (excl Interest) | 240.0M | 6.7B | 2.4B | 3.2B | 2.4B |
| EBT (Pre-Tax Income) | 6.2B | 41.0B | 45.6B | 23.7B | 23.0B |
| Income Tax Expense | 1.7B | 10.8B | 11.0B | 5.7B | 5.6B |
| Bottom Line | |||||
| Net Income | 28.1B | 28.1B | 32.4B | 16.7B | 16.5B |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 28.1B | 28.1B | 32.4B | 16.7B | 16.5B |
| Per Share | |||||
| Basic EPS | ¥376 | ¥376 | ¥427 | ¥220 | ¥216 |
| Diluted EPS | ¥376 | ¥376 | — | — | — |
| Revenue Per Share | ¥2,578 | ¥2,578 | ¥2,385 | ¥1,985 | ¥1,832 |
| Shares | |||||
| Basic Shares Outstanding | 74.7M | 74.7M | 75.9M | 76.0M | 76.4M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | 10.5B | 47.5B | 50.7B | 30.3B | 31.0B |
| D&A | 2.8B | 12.3B | 10.6B | 10.2B | 10.1B |
| EBIT | 35.2B | 35.2B | 40.1B | 20.0B | 20.9B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026